A landmark 2026 study in Nature Aging reveals that phosphoenolpyruvate (PEP), a glycolytic metabolite, acts as a natural brake on the cGAS-STING inflammatory pathway. As PEP levels decline with age, chronic inflammaging accelerates — and restoring PEP in animal models delays aging phenotypes and improves cognition.
First-generation senolytics like dasatinib plus quercetin showed only subtle effects in human trials. A new generation of senolytic CAR-T cells borrows cancer immunotherapy and retrains it to hunt senescent cells. Here is what the 2026 research reveals about the next frontier of cellular longevity medicine.
At the 2nd World Congress on Targeting Longevity in Berlin, researchers are proposing a paradigm shift: aging is not a collection of molecular defects to be fixed, but a progressive failure of biological communication between mitochondria, the microbiome, immunity, and metabolism. Here is what the science shows and what it means for how you age.
For the first time in history, a therapy designed to reverse the cellular age of human tissue is being tested in living patients. Here is what the science actually shows, and why the implications extend far beyond the eye. In January 2026, the U.S. Food and Drug Administration cleared Life Biosciences to begin the world’s…
A landmark Nature Aging expert review by 25 scientists, a Science Advances study showing NAD+ reverses Alzheimer’s memory deficits through RNA splicing, and the first human evidence that oral NAD+ precursors reach the brain are converging into one of the most promising cellular health stories of 2026. Here is what the research means for cognitive aging, sleep, and your healthspan.
New research from 2025 and 2026 confirms that zone 2 training, the low intensity aerobic exercise most people skip, is the single most effective way to build mitochondrial density, improve fat oxidation, protect cardiovascular health, and extend lifespan. Studies in Cell Metabolism, the British Journal of Sports Medicine, and Mayo Clinic Proceedings reveal why training at the top of your fat burning zone triggers biological adaptations that no amount of high intensity work can replicate.
ARPA-H’s $144 million PROSPR program is testing rapamycin, semaglutide, and dapagliflozin in 726 healthy older adults, funding a first-in-humans trial of a retrotransposon-silencing HIV drug, and building a validated biological healthspan score. It is the largest federal commitment to extending human healthspan ever assembled.
ARK Invest dumped $87 million in Nvidia and Meta last week and redirected capital into Tempus AI, GeneDx Holdings, CRISPR Therapeutics, and other healthcare AI and genomics companies. The signal is clear: the smartest capital allocators believe precision medicine is where AI delivers its greatest value.
The 2026 ACC/AHA guidelines formally recognize polygenic risk scores as a cardiovascular risk-enhancing factor for the first time. With a multi-ancestry PRS validated across 190,000 participants and the eMERGE Network returning genome-informed risk to 25,000 patients, precision cardiovascular medicine is moving from research labs into clinical practice, reclassifying 20 percent of borderline-risk patients and identifying hidden coronary plaque in seemingly healthy individuals.
Zach RobertsSign up for personalized wellness coaching and the Daily Discovery Newsletter.